SCHEMBL14747901

SCHEMBL14747901

Cc1ccc(N2CCC[C@H](C(N)=O)C2)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 1/20 0.49
PRKDC P78527 1/20 0.47
WDR91 A4D1P6 2/20 0.44
RAB9A P51151 2/20 0.43
PBK Q96KB5 1/20 0.42
SYK P43405 2/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
JAK3 P52333 1/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
NOTUM Q6P988 1/20 0.41
NPC1 O15118 1/20 0.41
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1911888 0.84 ZAP70 (0.49) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL12311809 0.84 ZAP70 (0.49) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL10207986 0.84 ZAP70 (0.49) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL29809917 0.83 NOTUM (0.51) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL22398883 0.83 NOTUM (0.51) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL2448228 0.82 WDR91 (0.51) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL1911872 0.81 ZAP70 (0.49) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL2559261 0.81 RAB9A (0.47) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL2445431 0.80 NOTUM (0.65) ALDH1A1HSD17B10KDM4EHPGDPRKDC
SCHEMBL2941204 0.80 NOTUM (0.64) NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275413-B1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-03-06 EP disclosed